Ulinastatin promotes epirubicin-induced apoptosis in liver cancer cells.

<p>(A) Percentage of surviving L02 cells treated with EPI/EPI+UTI/UTI. (B) Percentage of surviving SMMC-7721 and MHCC-LM3 liver cancer cells under the treatment of EPI/EPI+UTI/UTI for indicated times.(C, D) Western blot of indicated molecules were shown in SMMC-7721 and MHCC-LM3 liver cancer cells under the treatment of EPI/EPI+UTI (Treatment in D for 24 hr). ACTB was blotted as a loading control. (E) ANNEXIN V staining shows the percentage of cells underwent apoptosis under the treatment of EPI/EPI+UTI for indicated times. Left panel was average result of 3 experiments; right panel was representative result. Results are average of 3 independent experiments, (*P<0.05,**P<0.01).